Clinically proven weight loss. Your choice of treatment.
Tirzepatide or semaglutide — FDA-approved GLP-1 options prescribed by licensed providers. Shipped direct from LillyDirect or NovoCare Pharmacy at the manufacturer’s self-pay rate, or sent to a local pharmacy you choose.
Available treatments
Three FDA-approved GLP-1 options — two tirzepatide formulations and semaglutide. Your provider will recommend the best fit based on your health profile.
Zepbound®
tirzepatide injection
Dual GIP + GLP-1 receptor agonist
- Only dual-action GIP + GLP-1 approved for weight loss
- Once-weekly subcutaneous injection
- Gradual dose titration (2.5 mg → 15 mg)
- Pre-filled single-use pen — no mixing required
- Ships from the manufacturer's pharmacy or your local pharmacy
Adults with BMI ≥30, or BMI ≥27 with a weight-related condition
Once-weekly pre-filled pen
Foundayo™
tirzepatide oral
Dual GIP + GLP-1 receptor agonist
- Same active ingredient as Zepbound — in a daily pill
- No injections required
- Oral tablet taken once daily on an empty stomach
- Gradual dose escalation over several weeks
- Ships from the manufacturer's pharmacy or your local pharmacy
Adults with BMI ≥30, or BMI ≥27 with a weight-related condition
Once-daily tablet
Wegovy®
semaglutide injection
GLP-1 receptor agonist
- FDA-approved for chronic weight management in adults
- Once-weekly subcutaneous injection
- Gradual dose escalation (0.25 mg → 2.4 mg over 16 weeks)
- Pre-filled single-use pen — no mixing required
- Good option for patients who prefer semaglutide over tirzepatide
Adults with BMI ≥30, or BMI ≥27 with a weight-related condition
Once-weekly pre-filled pen
How it works
From assessment to your door (or local pharmacy) in four straightforward steps.
Check your eligibility
Enter your email to be notified as soon as we begin accepting patients.
Complete your assessment
A 5-minute health questionnaire reviewed by a licensed provider in your state.
Get your prescription
If approved, your provider routes the Rx to LillyDirect, NovoCare Pharmacy, or a local pharmacy you choose.
Receive & ongoing care
Your medication ships to your door from the manufacturer pharmacy or is ready for pickup locally. Your provider manages dosing and follow-ups.
The science behind tirzepatide
Tirzepatide is the only FDA-approved weight loss compound that activates both GIP and GLP-1 receptors, delivering superior results to semaglutide (Wegovy) in head-to-head comparisons. It's our primary recommendation for most patients.
maximum body weight reduction in SURMOUNT-1 trials
first and only GIP + GLP-1 receptor agonist for weight loss
injectable option — or once daily with the oral tablet
of clinical trial data supporting sustained weight loss
Am I eligible?
These medications are FDA-approved for adults who meet specific criteria. A licensed provider will confirm your eligibility.
Frequently asked questions
What is the difference between Zepbound and Foundayo?
Both contain tirzepatide, the same active ingredient made by Eli Lilly. Zepbound is a once-weekly injection using a pre-filled pen. Foundayo is a once-daily oral tablet. They have comparable clinical efficacy — the choice between them typically comes down to patient preference and provider recommendation.
Do I need to choose between injection and pill?
No — your licensed provider will discuss both options with you and recommend the best fit based on your health profile, lifestyle, and goals.
Why can’t I sign up right now?
Valitide is in a pre-launch phase while we finalize our licensed-provider network. Join the waitlist and we’ll notify you the moment intake opens in your state. Early-waitlist members will be first to be reviewed.
Do I need insurance?
No — Valitide is built for direct-pay access. We don't bill insurance and we don't handle prior authorizations. Your prescription routes directly to the manufacturer's self-pay pharmacy: LillyDirect for Zepbound or Foundayo, or NovoCare Pharmacy for Wegovy. You pay the manufacturer's published self-pay rate plus a flat Valitide subscription for your care team.
How does shipping work?
Once your provider approves your prescription, the Rx is sent electronically to whichever pharmacy you choose at intake. LillyDirect (Zepbound) and NovoCare Pharmacy (Wegovy) ship the medication directly to your door at the manufacturer's self-pay rate. If you'd rather pick up locally, you can choose any retail pharmacy you prefer instead — the prescription is transmitted electronically.
How does Wegovy (semaglutide) compare to Zepbound?
Both are FDA-approved GLP-1 medications for weight loss. Zepbound (tirzepatide) activates two receptors — GLP-1 and GIP — and produced up to 22.5% body weight reduction in clinical trials. Wegovy (semaglutide) targets only GLP-1 and produced up to 17% weight loss. Clinically, tirzepatide is the stronger option. That said, Wegovy is a great fit if you've previously responded well to it or prefer semaglutide. Your provider will help you choose.
How much weight can I expect to lose?
In clinical trials, participants on tirzepatide lost up to 22.5% of their body weight over 72 weeks. Individual results vary based on dosing, diet, exercise, and adherence.
Ready to get started?
Complete a free 5-minute eligibility check to see if GLP-1 medication is right for you.
Get StartedNo commitment required. Your information is kept private and secure.
Important Safety Information:Zepbound®, Foundayo™ (tirzepatide), and Wegovy® (semaglutide) are prescription medications and are not for everyone. Do not use if you or your family have ever had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Serious side effects may include pancreatitis, gallbladder problems, kidney problems, and serious allergic reactions. Common side effects include nausea, diarrhea, decreased appetite, vomiting, constipation, and stomach pain. Zepbound® and Foundayo™ are registered trademarks of Eli Lilly and Company. Wegovy® is a registered trademark of Novo Nordisk. Valitide LLC is not affiliated with or endorsed by Eli Lilly and Company or Novo Nordisk. All prescriptions are at the sole discretion of a licensed provider.